SEC Form 4 · accession 0001479290-17-000044
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren P Silvernail
Officer — CFO, CBO & Secretary
Period of report
Dec 26, 2017
Accepted (ET)
Dec 28, 2017 · 8:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 26, 2017 | M | 17,506 | $8.70 | A | 66,512 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F2 | $8.70 | Dec 26, 2017 | M | 17,506 | D | — | May 23, 2023 | Common Stock | 17,506 | 45,867 | D |
Explanation of responses
- F1Mrs. Silvernail has exercised the option on December 26, 2017 and paid the exercise price in cash.
- F2The Option became fully vested as of March 18, 2017.